比较不同剂量血脂康对急性冠脉综合征患者血脂水平及炎症因子的影响  

To compare the Effects of Different Dose Xuezhikang with Provastatin on Blood Lipids and Inflammatory Factors in Patients with Acute Coronary Syndrome

作　　者：王敏[1] 沈建瑾[1] 黄世恩[1] 姚强[1] 

机构地区：[1]浙江省中西医结合医院,浙江杭州310003

出　　处：《心脑血管病防治》2005年第5期14-16,共3页CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT

摘　　要：目的比较不同剂量血脂康与普伐他汀治疗急性冠脉综合征(ACS)对血脂水平及血清炎症因子的影响,探讨ACS患者早期应用血脂康的临床意义.方法 96例ACS患者随机分为血脂康1.2g/d组(n=32)、血脂康2.4g/d组(n=32)及对照组普伐他汀20mg/d(n=32).测定治疗前、治疗8周时血脂水平及血清hsCRP、IL-6水平.结果 (1)三组治疗8周时与治疗前比较,TC、LDL-C、TG水平均显著降低(P＜0.05或P＜0.01);hsCRP、IL-6水平降低也有显著性差异(P＜0.05或P＜0.01).(2)三组治疗8周时组间比较,hsCRP、IL-6水平血脂康1.2g/d组较普伐他汀20mg/d对照组降低明显有显著性差异(P＜0.05);血脂康2.4g/d组较1.2g/d组降低明显有显著性差异(P＜0.01).结论急性冠脉综合征患者早期给予血脂康1.2～2.4g/d调脂作用与普伐他汀20mg/d无明显差异,但降低炎症因子作用强于普伐他汀20mg/d.Objective To compare the effects of different dose xuezhikang with provastatin on blood lipids and inflammatory factorsin patients with acute coronary syndrome （ACS）. Methods 96 patients with ACS were divided randomly into xuezhikang 1.2g/d group, xuezhikang 2.4g/d group and provastatin 20mg/d group. There are 32 patients in each group. The level of blood lipids including TC, LDL- C, TG, HDL- C and inflammatory factors including high- sensitivity C- reactive protein （hsCRP）, interleukin- 6 （IL- 6） were detected before and after 8 week＇s treatment. Results （1） After 8 week＇ s treatment, TC, LDL- C, TG significantly decreased （ P 〈 0.01 or 0.05） in all three groups compared with before treatment, but there was no significantly difference among three groups （ P 〉 0.05）. （ 2 ） After 8 week＇s treatment, hsCRP, IL-6 significantly decreased （P 〈0.01 or 0.05） in all three groups compared with before treatment. IL-6 and hsCRP decreased significantly in xuezhikang 1.2g/d group than those in provastatin 20mg/d group（ P 〈 0.05） and they decreased more significantly in xuezhikang 2.4g/d group than those in xuezhikang 1.2g/d group（ P 〈 0.01 ）. Conclusions In ACS early stage, the use of xuezhikang 1.2 - 2.4g/d or provastatin 20mg/d could significantly reduce blood lipids and inflammatory factors. The effect of reducing blood lipids has no significant difference among these groups, but the effect of decreasing inflammatory factors was more obvious in xuezhikang 1.2 - 2.4g/d than in provastatin 20mg/d. The decreasing inflammatory factors effect of xuezhikang was independent of reducing blood lipids effect.

关 键 词：急性冠脉综合征 血脂康 普伐他汀 高敏C-反应蛋白 白介素-6 

分 类 号：R541.4[医药卫生—心血管疾病]